This product will cause a dramatic increase in fat burning
without exercise even though I always suggest exercise. Along with that it
reduces your cholesterol levels and testing in lab rats have shown to prevent
diabetes. The ingredients in ThyroTwin will shift your metabolism into
the fat burning mode even faster than some prescription medications.
3,5-diiido-I-thyronine does not have the negative side effects often associated
with prescription meds. Clinical research shows that mammals live longer and
much healthier with higher levels of 3.5 than those who have lower levels.
Here is a personal example: a client of mine used ThyroTwin and
after one week, noticed his waist stared to flatten. At age 53, he also noticed
he was getting his abs back he once had in his 20's! In the third week,
my client noticed he was getting very lean while maintaining his weight meaning
he was turning fat into muscle.
One thing I was told by the manufacture that ThyroTwin helps
your body release growth hormone which a direct benefit is getting lean.
His strength went up by 25% at the end of the 4 week cycle as well and told me
he is a customer for life thanking me for recommending him the ThyroTwin.
If you have a job where you sit all day or are otherwise
sedentary, ThryoTwin is an awesome way to turn fat into muscle, lower
cholesterol and potentially reduce the risk of diabetes.
For those of you
into the science, see the below brief. These studies are fairly tech-heavy but
they CLEARLY show that 3,5-diiido-l-thyronine (and 3,3'-diiido-l-thyronine):
Side Note:
Because the effects of thyroid drugs like cytomel and synthroid in
humans are analogous to the effects in other mammals (such as rats), there has
been a lot of activity (especially lately) on rat studies comparing
3,5-diiido-l-thyronine (because of its effectiveness and safety) to the current
pharmaceutical drugs mentioned. 3,3'-diiido-l-thyronine has fewer studies than
3,5-. Although incredibly effective and less suppressive than all the others,
it's extremely expensive and a much more complex chemical to
synthesize. For this reason, it is not commercially viable to big pharma and
therefore doesn't warrant the funding of full scale clinical studies. Unfortunately
for our industry, it seems probable that all the recent clinical activity on
these compounds in the last year suggests that pharma is looking to market them
as drugs in the future.
“The role of thyroid hormone (3,5,3'-triiodothyronine
or "T3" or "Cytomel") as a major endocrine regulator of
metabolic rate is widely recognized [J Clin Invest 87:125-132, 1991]. In fact,
in adults T3 is unique in its ability to stimulate thermogenesis and to affect
anabolic and catabolic biochemical processes. In lipid/fat metabolism, T3
affects the synthesis, mobilization, and degradation of lipids and fats,
although degradation is influenced more rapidly than synthesis [Physiol Rev
86435-464, 2006]. Indeed, T3 increases 1) the
mobilization of the triglycerides stored in fatty tissue, 2) the
serum concentrations of free fatty acids (FFA), 3) lipoprotein
lipase activity, and 4) the utilization of lipid/fat
substrates in metabolically active tissues [Biochm J 437:125-134, 2011]. Under
certain conditions, these effects are accompanied by a reduction in body weight
[Nat Rev Drug Discov 8:308-320, 2009].
As a result, in the past T3 has been proposed and
tentatively used as an antiobesity and lipid-lowering agent. However, its
beneficial weight reduction effects were associated with the simultaneous
induction of a thyrotoxic state and with undesirable side effects on the heart
and cardiovascular system, and so its use for such purposes has been stopped
(Curr Opin Investig Drugs 10: 912-918, 2009]. Now, in the hope of
counteracting dyslipidemia, high cholesterol and obesity, attention is being
focused on the development of compounds that have the beneficial effects of
excess thyroid hormone, but with minimal deleterious effects [Nat Clin Pract
Endocrinol Metab 3: 632-640, 2007]. In particular, new perspectives in
this field have been opened by the introduction of potent thyromimetics with
thyroid hormone receptor-beta isoform (TR-beta) sub- type selective activities
[Curr Opin Investig Drugs 10: 912-918, 2009], and a few of them have recently
entered clinical trials [N Engl J Med 62: 906-916, 2010]. Importantly, TR-beta
receptors are scarcely expressed at all in cardiomyocytes in the heart and are
involved mainly in the thyroid hormone-mediated regulation of lipid metabolism
[Thyroid 18, 197-203, 2008].
There is accumulating evidence to show that 3,5-T2, a
thyroid hormone derivative, has biological effects both in vivo and in vitro
[Biochemistry (Mosc) 70: 164-172, 2005]. 3,5-T2 is able to positively
affect both energy and lipid/fat metabolism without inducing the side effects
associated with T3 [Diabetes 60: 2730-2739, 2011]. It has been
conclusively demonstrated that, 3,5-T2 administration to mammals increases
their resting metabolic rate [J Physiol 505: 529-538, 1997] and prevents
diet-induced obesity as well as hypertriglyceridemia, hypercholesterolemia
[Diabetes 60: 2730-2739, 2011 & FASEB J 19: 1552-1554, 2005], and insulin
resistance [FASEB J 25: 3312-3324, 2011]. Even more recent studies
[Int J Mol Sci 14, 2013 & Biochim Biophys Acta 1832: 674-684, 2013]
have shown that 3,5-T2 may have a role in anti-aging and that the
administration of 3,5-T2 may effect SIRT1 genes in a manner similar to dietary
supplement, resveratrol.”
This is some pretty impressive stuff to say the least. Its
rare we get something that legitimately works like this in our industry.
Barry
No comments:
Post a Comment